
Frankie L. Stinson
Examiner (ID: 8117)
| Most Active Art Unit | 1746 |
| Art Unit(s) | 1792, 1711, 2402, 1746, 2899, 3405, 1743 |
| Total Applications | 3621 |
| Issued Applications | 3013 |
| Pending Applications | 138 |
| Abandoned Applications | 470 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16734385
[patent_doc_number] => 10960006
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Topical formulations comprising tofacitinib
[patent_app_type] => utility
[patent_app_number] => 16/254076
[patent_app_country] => US
[patent_app_date] => 2019-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 7438
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16254076
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/254076 | Topical formulations comprising tofacitinib | Jan 21, 2019 | Issued |
Array
(
[id] => 15267297
[patent_doc_number] => 20190382382
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/252458
[patent_app_country] => US
[patent_app_date] => 2019-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16252458
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/252458 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | Jan 17, 2019 | Abandoned |
Array
(
[id] => 14306181
[patent_doc_number] => 20190142794
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE B AND ADP RECEPTOR ANTAGONIST, PREPARATION METHOD THEREOF AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/244593
[patent_app_country] => US
[patent_app_date] => 2019-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7688
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16244593
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/244593 | Pharmaceutical composition containing Ginkgolide B and ADP receptor antagonist, preparation method thereof and use thereof | Jan 9, 2019 | Issued |
Array
(
[id] => 14309445
[patent_doc_number] => 20190144426
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/243400
[patent_app_country] => US
[patent_app_date] => 2019-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 95657
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16243400
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/243400 | Quinazolines as potassium ion channel inhibitors | Jan 8, 2019 | Issued |
Array
(
[id] => 16590490
[patent_doc_number] => 10899740
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-26
[patent_title] => Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
[patent_app_type] => utility
[patent_app_number] => 16/241596
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 19093
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241596
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/241596 | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide | Jan 6, 2019 | Issued |
Array
(
[id] => 18503571
[patent_doc_number] => 11701361
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-18
[patent_title] => p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
[patent_app_type] => utility
[patent_app_number] => 16/959960
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 37
[patent_no_of_words] => 12047
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959960
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/959960 | p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens | Jan 6, 2019 | Issued |
Array
(
[id] => 15253993
[patent_doc_number] => 20190375730
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT
[patent_app_type] => utility
[patent_app_number] => 16/240587
[patent_app_country] => US
[patent_app_date] => 2019-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240587
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/240587 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | Jan 3, 2019 | Abandoned |
Array
(
[id] => 18101160
[patent_doc_number] => 11541028
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Peptide pharmaceuticals for treatment of NASH and other disorders
[patent_app_type] => utility
[patent_app_number] => 16/958597
[patent_app_country] => US
[patent_app_date] => 2019-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 65
[patent_figures_cnt] => 89
[patent_no_of_words] => 29760
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958597
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/958597 | Peptide pharmaceuticals for treatment of NASH and other disorders | Jan 2, 2019 | Issued |
Array
(
[id] => 16390930
[patent_doc_number] => 20200331871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => METHOD FOR PRODUCING LACTAM COMPOUND, AND LACTAM COMPOUND PRODUCED THEREBY
[patent_app_type] => utility
[patent_app_number] => 16/959863
[patent_app_country] => US
[patent_app_date] => 2019-01-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10661
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959863
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/959863 | Method for producing lactam compound, and lactam compound produced thereby | Jan 1, 2019 | Issued |
Array
(
[id] => 16405393
[patent_doc_number] => 10813930
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-27
[patent_title] => Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
[patent_app_type] => utility
[patent_app_number] => 16/238277
[patent_app_country] => US
[patent_app_date] => 2019-01-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23461
[patent_no_of_claims] => 42
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1857
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16238277
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/238277 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | Jan 1, 2019 | Issued |
Array
(
[id] => 16999415
[patent_doc_number] => 11078206
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-03
[patent_title] => Amino-fluoropiperidine derivatives as kinase inhibitor
[patent_app_type] => utility
[patent_app_number] => 16/770642
[patent_app_country] => US
[patent_app_date] => 2018-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4357
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16770642
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/770642 | Amino-fluoropiperidine derivatives as kinase inhibitor | Dec 27, 2018 | Issued |
Array
(
[id] => 17875488
[patent_doc_number] => 11447489
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Dihydropyrimidinylthiazole for the treatment and prophylaxis of hepatitis B virus infection
[patent_app_type] => utility
[patent_app_number] => 16/958658
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12545
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958658
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/958658 | Dihydropyrimidinylthiazole for the treatment and prophylaxis of hepatitis B virus infection | Dec 20, 2018 | Issued |
Array
(
[id] => 17587642
[patent_doc_number] => 11325896
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-10
[patent_title] => Antagonists of the muscarinic acetylcholine receptor M4
[patent_app_type] => utility
[patent_app_number] => 16/955265
[patent_app_country] => US
[patent_app_date] => 2018-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20543
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 235
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955265
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955265 | Antagonists of the muscarinic acetylcholine receptor M4 | Dec 19, 2018 | Issued |
Array
(
[id] => 18260651
[patent_doc_number] => 11608345
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-03-21
[patent_title] => Lipid prodrugs of rapamycin and its analogs and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/955084
[patent_app_country] => US
[patent_app_date] => 2018-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 81759
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955084
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955084 | Lipid prodrugs of rapamycin and its analogs and uses thereof | Dec 18, 2018 | Issued |
Array
(
[id] => 17539850
[patent_doc_number] => 11304954
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-19
[patent_title] => Lipid prodrugs of mycophenolic acid and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/955162
[patent_app_country] => US
[patent_app_date] => 2018-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 19
[patent_no_of_words] => 95336
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955162
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955162 | Lipid prodrugs of mycophenolic acid and uses thereof | Dec 18, 2018 | Issued |
Array
(
[id] => 16735616
[patent_doc_number] => 10961252
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Quinazoline and indole compounds to treat medical disorders
[patent_app_type] => utility
[patent_app_number] => 16/226378
[patent_app_country] => US
[patent_app_date] => 2018-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61781
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 700
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16226378
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/226378 | Quinazoline and indole compounds to treat medical disorders | Dec 18, 2018 | Issued |
Array
(
[id] => 16343545
[patent_doc_number] => 20200308195
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => DIAZAINDOLE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/955108
[patent_app_country] => US
[patent_app_date] => 2018-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21136
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955108
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955108 | Diazaindole compounds | Dec 17, 2018 | Issued |
Array
(
[id] => 16822632
[patent_doc_number] => 20210137925
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/954801
[patent_app_country] => US
[patent_app_date] => 2018-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13602
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954801
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/954801 | Targeting mitochondrial fission through mDIVI-1 derivatives | Dec 17, 2018 | Issued |
Array
(
[id] => 16908901
[patent_doc_number] => 11040925
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-22
[patent_title] => 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 16/222280
[patent_app_country] => US
[patent_app_date] => 2018-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 25145
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 443
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16222280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/222280 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | Dec 16, 2018 | Issued |
Array
(
[id] => 16749889
[patent_doc_number] => 20210101898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => AMIDE SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH A BRANCHED CHAIN LINKING GROUP FOR USE AS AN IMMUNE RESPONSE MODIFIER
[patent_app_type] => utility
[patent_app_number] => 15/733207
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19249
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733207
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/733207 | Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier | Dec 13, 2018 | Issued |